Bladder Cancer Trials
Phase 2 Clinical Trial in Metastatic Bladder Cancer (Borealis-1)
This trial is designed to evaluate a potential survival benefit of OGX-427 in combination with the standard of care first-line chemotherapy, gemcitabine and cisplatin, for patients with metastatic bladder cancer. The trial will enroll approximate 180 patients and is open throughout North America and at various cancer centers in Europe.
To learn more about the Borealis -1 Trial please visit OGX-427 Phase 2 Bladder Cancer Trial.
Phase 2 Clinical Trial in Metastatic Bladder Cancer (Borealis-2)
This trial is designed to evaluate overall survival, with secondary objectives evaluating safety, tolerability, tumor response rates and the effect of therapy on Hsp27 levels and circulating tumor cells. The trial will enroll approximate 200 patients at approximately 30 sites in the U.S. and is being sponsored by the Hoosier Oncology Group.
To learn more about the Borealis-2 Trial please visit OGX-427 Phase 2 Bladder Cancer Trial.
Phase 1 Clinical Trial in Superficial or Non-Muscle Invasive Bladder Cancer
This trial, funded by the National Cancer Institute of Canada, will evaluate the potential benefit of OGX-427 when directly infused into the bladder of patients with superficial or non-invasive bladder cancer.
To learn more about the OGX-427 Phase 1 Bladder Cancer Trial please visit OGX-427 Phase 1 Bladder Cancer Trial.